Cardio Diagnostics Holdings, Inc. (CDIO) Aandelenanalyse

Bedrijfsoverzicht

Cardio Diagnostics Holdings, Inc. is a biotechnology firm focused on the development and commercialization of epigenetics-based clinical tests designed to assess cardiovascular disease risk. Operating within the healthcare sector specifically under the biotechnology industry classification, the company targets specific clinical needs such as symptomatic coronary heart disease and heart attack risk assessment through its Epi+Gen CHD blood test. The entity currently maintains a market capitalization of $5.42 million, generates annual revenue of $14,825, and employs a workforce of 15 individuals. These financial and operational metrics indicate that the company operates as a micro-cap enterprise with minimal revenue scale relative to its market valuation, suggesting a position in the early-stage or highly specialized niche of the healthcare market rather than a mature commercial entity.

Financiële gezondheid

The company reported revenue of $14,825 over the trailing twelve months, yet recorded a net income of -$6,498,167 and an EBITDA of -$6,085,950. The substantial negative net income relative to the negligible revenue figure reveals a cost structure characterized by extremely high operating expenses that far exceed current sales generation, a pattern common in pre-revenue or early-revenue biotechnology firms. Free cash flow stands at -$3,809,743, indicating that the company is consuming its cash reserves to fund research and development activities rather than generating liquidity from operations. The gross margin is reported at 100.0%, which typically reflects a service or early-stage product model where cost of goods sold is negligible compared to revenue, while the operating margin of -41159.6% and profit margin of 0.0% highlight severe operational losses and an inability to convert revenue into profit at this stage. The balance sheet holds $5.11 million in cash against $695,619 in debt, resulting in a debt-to-equity ratio of 9.97, which suggests a highly leveraged capital structure relative to equity but provides a significant cash buffer against the outstanding liabilities. Additionally, the current ratio is 9.79, indicating a very strong short-term liquidity position where current assets significantly exceed current liabilities. Return on equity is -78.6% and return on assets is -44.1%, metrics that demonstrate the company is currently destroying shareholder value and utilizing assets to generate negative returns rather than positive profitability.

Waarderingsbeoordeling

The trailing twelve-month P/E ratio is listed as N/A due to the negative earnings, while the forward P/E is reported as -7.32, implying that market expectations for future earnings remain negative or that the market is pricing in a path to profitability that has not yet been realized. The price-to-book ratio stands at 0.48, indicating that the market values the company at less than its book value, suggesting a lack of market premium over the net asset value often seen in distressed or speculative biotech stocks. Alternative valuation metrics include a price-to-sales ratio of 365.32 and an EV/EBITDA of -0.16, figures that suggest the market is willing to pay a massive multiple on sales despite the lack of profitability, reflecting high expectations for future commercial success from its epigenetics tests. The stock has traded between a 52-week low of $0.97 and a 52-week high of $17.40, meaning the current price sits at a level that reflects significant volatility and a wide trading range within the year. The beta value is 2.66, which signifies that the stock price is highly sensitive to market movements and exhibits substantially higher volatility than the broader market index.

Growth & Income

Revenue growth year-over-year is -21.2%, while earnings growth is N/A, indicating that the company is currently shrinking in terms of top-line sales and has no positive earnings growth to offset this decline. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders but instead retains all earnings or cash flow to fund internal growth initiatives and R&D efforts. The absence of a dividend yield confirms that the company reinvests its limited financial resources back into the business to attempt to achieve commercial viability rather than providing income to investors. The overall growth and income profile for Cardio Diagnostics Holdings, Inc. is defined by negative revenue contraction and a complete reliance on capital markets or cash reserves to sustain operations without providing any current income stream or positive earnings growth trajectory.